The conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheses.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic theoretical framework without systematic review methodology or new human data
PubMed 42459575 · doi:10.1177/17562864261465665
What was done
This narrative review searched the PubMed database for peer-reviewed literature published up to December 10, 2025, to evaluate the mechanistic rationale behind alpha-synuclein-targeted immunotherapies in Parkinson's disease, assess reasons for recent Phase II/III clinical trial failures (including trials of cinpanemab and prasinezumab), and propose alternative metabolic frameworks.
What was found
The abstract reports no primary statistical outcomes or pooled effect sizes. It notes that major clinical trials targeting extracellular alpha-synuclein failed to demonstrate clinical efficacy. The authors propose the 'Single-Neuron Degeneration Hypothesis', arguing that pathology is driven cell-intrinsically by intracellular autotoxicity (involving aminochrome, mitochondrial dysfunction, and oxidative stress) rather than extracellular prion-like spread. They cite multifactorial reasons for trial failure, including inadequate preclinical models like MPTP, insensitivity of the MDS-UPDRS scale, diagnostic heterogeneity, and a very slow estimated human neuronal loss rate of approximately 60 neurons per day.
Why it matters
This paper synthesizes potential explanations for the failure of major disease-modifying antibody trials in Parkinson's disease, proposing a conceptual shift from extracellular clearance to intracellular neuroprotection and NRF2 pathway activation.
Limits
The paper is a narrative review without systematic search protocols, quantitative meta-analysis, or new primary experimental/clinical data. The proposed 'Single-Neuron Degeneration Hypothesis' is theoretical mechanism-based reasoning that requires empirical validation.
Cited by
- supports There are currently no meaningful disease-modifying treatments for neurodegenerative diseases like Alzheimer's and Parkinson's disease that address the underlying disease process.